Hubbry Logo
5-HT2C receptor5-HT2C receptorMain
Open search
5-HT2C receptor
Community hub
5-HT2C receptor
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
5-HT2C receptor
5-HT2C receptor
5-HT2C receptor
View on Wikipedia
from Wikipedia
HTR2C
Identifiers
AliasesHTR2C, 5-HT2C, 5-5HTR1C, 5-HT1C, 5-HT2C receptor, 5-hydroxytryptamine receptor 2C
External IDsOMIM: 312861; MGI: 96281; HomoloGene: 20242; GeneCards: HTR2C; OMA:HTR2C - orthologs
Orthologs
SpeciesHumanMouse
Entrez

3358

15560

Ensembl

n/a

ENSMUSG00000041380

UniProt

P28335

P34968

RefSeq (mRNA)

NM_001256761
NM_000868
NM_001256760

NM_008312

RefSeq (protein)

NP_000859
NP_001243689
NP_001243690

NP_032338

Location (UCSC)n/aChr X: 145.75 – 145.98 Mb
PubMed search[2][3]
Wikidata
View/Edit HumanView/Edit Mouse

The 5-HT2C receptor is a subtype of the 5-HT2 receptor that binds the endogenous neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). Like all 5-HT2 receptors, it is a G protein-coupled receptor (GPCR) that is coupled to Gq/G11 and mediates excitatory neurotransmission. HTR2C denotes the human gene encoding for the receptor,[4][5] that in humans is located on the X chromosome. As males have one copy of the gene and females have one of the two copies of the gene repressed, polymorphisms at this receptor can affect the two sexes to differing extent.

Structure

[edit]

At the cell surface the receptor exists as a homodimer.[6] The crystal structure has been known since 2018.[7]

Distribution

[edit]

5-HT2C receptors are located mainly in the choroid plexus,[8] and in rats is also found in many other brain regions in high concentrations, including parts of the hippocampus, anterior olfactory nucleus, substantia nigra, several brainstem nuclei, amygdala, subthalamic nucleus and lateral habenula. 5-HT2C receptors are also found on epithelial cells lining the ventricles.[9]

Function

[edit]

The 5-HT2C receptor is one of the many binding sites for serotonin. Activation of this receptor by serotonin inhibits dopamine and norepinephrine release in certain areas of the brain.[10]

5-HT2C receptors are claimed to significantly regulate mood, anxiety, feeding, and reproductive behavior.[11] 5-HT2C receptors regulate dopamine release in the striatum, prefrontal cortex, nucleus accumbens, hippocampus, hypothalamus, and amygdala, among others.

Research indicates that some suicide victims have an abnormally high number of 5-HT2C receptors in the prefrontal cortex.[12] Agomelatine, which is a 5-HT2C and 5-HT2B antagonist as well as a MT1 and MT2 agonist, is an effective antidepressant.[13][14] It has been found to act, through its 5-HT2C receptor antagonism, as a norepinephrine-dopamine disinhibitor because antagonism of 5-HT2C results in an increase of dopamine and norepinephrine activity in the frontal cortex.[15]

Conversely, many atypical antipsychotic and antidepressants act as 5-HT2C receptor antagonists,, like Loxapine, an antipsychotic structurally related to Clozapine and its metabolite Amoxapine, which is an antidepressant in its own right, act as 5-HT2C receptor antagonist.[16] Fluoxetine acts as a direct 5-HT2C antagonist in addition to inhibiting serotonin reuptake, however, the clinical significance of this action is variable.[17] Several tetracyclic antidepressants, including mirtazapine and Mianserin,[15] as well as certain Tricyclic antidepressant such as Amitriptyline and Clomipramine[18] are potent 5-HT2C antagonists; this action may contribute to their efficacy.[19][20][21][15] An overactivity of 5-HT2C receptors may contribute to depressive and anxiety symptoms in a certain population of patients. Activation of 5-HT2C by serotonin is responsible for many of the negative side effects of SSRI and SNRI medications, such as sertraline, paroxetine, venlafaxine, and others. Some of the initial anxiety caused by SSRIs is due to excessive signalling at 5-HT2C receptors. 5-HT2C receptors exhibit constitutive activity in vivo, and may retain the ability to influence neurotransmission in the absence of ligand occupancy. Thus, 5-HT2C receptors do not require binding by a ligand (serotonin) in order to exhibit influence on neurotransmission. Inverse agonists may be required to fully extinguish 5-HT2C constitutive activity, and may prove useful in the treatment of 5-HT2C-mediated conditions in the absence of typical serotonin activity.[22] In addition to the evidence for a role of 5-HT2C receptor stimulation in depressive symptoms there also is evidence that activation of 5-HT2C receptors may have beneficial effects upon certain aspects of depression, one group of researchers found that direct stimulation of 5-HT2C receptors with a 5-HT2C agonist reduced cognitive deficits in mice with a TPH2 loss-of-function mutation.[23]

5-HT2C receptors mediate the release and increase of extracellular dopamine in response to many drugs,[24][25] including caffeine, nicotine, amphetamine, morphine, cocaine, and others. 5-HT2C antagonism increases dopamine release in response to reinforcing drugs, and many dopaminergic stimuli. Feeding, social interaction, and sexual activity all release dopamine subject to inhibition of 5-HT2C. Increased 5-HT2C expression reduces dopamine release in both the presence and absence of stimuli.

Conditions that increase cytokine levels in the human body may have potential to raise 5-HT2C gene expression in the brain. This could possibly comprise a link between viral infections and associated depression. Cytokine therapy has been shown to increase 5-HT2C gene expression, resulting in increased activity of 5-HT2C receptors in the brain [citation needed].

Endocrinology

[edit]

Serotonin is involved in basal and stress-induced regulation of hypothalamus and pituitary gland hormones such as prolactin, adrenocorticotropic hormone (ACTH), vasopressin and oxytocin, mainly via actions of receptor subtypes 5-HT2A and 5-HT2C.[26] Therefore, the 5-HT2C receptor is a significant modulator of the hypothalamic–pituitary–adrenal axis (HPA axis).[27] The HPA axis is the main controller of acute sympathetic stress responses related to fight-or-flight response. Prolonged activation and disturbances of the HPA axis contribute to depressive and anxiety symptoms seen in many psychopathological conditions.

Stimulation of 5-HT2C receptors leads to increase of corticotropin releasing hormone (CRH) and vasopressin mRNA in the paraventricular nucleus and proopiomelanocortin in the anterior pituitary lobe. In rats, restraint stress (which can produce depressive symptoms if being chronic) induces secretion of prolactin, ACTH, vasopressin and oxytocin which is partially mediated via 5-HT2C receptor. Responses during such conditions as dehydration or haemorrhage causes the release of oxytocin via serotonergic response that is partly mediated by 5-HT2C. In addition, peripheral release of vasopressin involves serotonergic response which is partially mediated via 5-HT2C.

Expression of the 5-HT2C receptor in the CNS is modulated by female sex hormones estradiol and progesterone. Combination of the hormones decrease the receptor concentration in the ventral hippocampus in rats and could thus affect mood.[28]

Genetics

[edit]

Many human polymorphisms have been identified influencing the expression of 5-HT2C. Significant correlations are suggested, specifically in relation to psychiatric disorders such as depression, OCD, and anxiety-related conditions. Polymorphisms also correlate with susceptibility to a number of conditions including substance use disorders and obesity. There are indications that the alternative splicing of the 5-HT2C receptor is regulated by a snoRNA called SNORD115, the deletion of which is associated with Prader–Willi syndrome.[29][30] As the human gene is located in the X chromosome, males have only one copy of the gene whereas women have two, meaning that mutations in the gene affect the phenotype of men even when the allele would be recessive in nature. As women have two copies of the gene, but only one allele is expressed in each cell, they are a mosaic for polymorphisms, meaning that one genetic variant may be prevalent in one tissue and another variant will be prevalent in a different tissue (as with all other x-linked genetic variations).

Ligands

[edit]

Agonists

[edit]
Main article: 5-HT2C receptor agonist

Partial agonists

[edit]

Antagonists

[edit]

Peripherally selective antagonists

[edit]

Inverse agonists

[edit]

Positive allosteric modulators

[edit]

Exogenous PAMs of the serotonin 5-HT2C receptor include:[37]

Interactions

[edit]

The 5-HT2C receptor has been shown to interact with MPDZ.[41][42]

RNA editing

[edit]

5HT2CR pre-mRNA can be the subject of RNA editing.[43] It is the only serotonin receptor as well as the only member of the large family of 7 transmembrane receptors (7TMRs) known to be edited. Different levels of editing result in a variety of effects on receptor function.

Type

[edit]

The type of RNA editing that occurs in the pre-mRNA of the 5HT2CR is Adenosine to Inosine (A to I) editing.

A to I RNA editing is catalyzed by a family of adenosine deaminases acting on RNA (ADARs) that specifically recognize adenosines within double-stranded regions of pre-mRNAs and deaminate them to inosine. Inosines are recognised as guanosine by the cells translational machinery. There are three members of the ADAR family ADARs 1–3 with ADAR1 and ADAR2 being the only enzymatically active members. ADAR3 is thought to have a regulatory role in the brain. ADAR1 and ADAR2 are widely expressed in tissues while ADAR3 is restricted to the brain. The double stranded regions of RNA are formed by base-pairing between residues in the close to region of the editing site with residues usually in a neighboring intron but can be an exonic sequence. The region that base pairs with the editing region is known as an Editing Complementary Sequence (ECS).

ADARs bind interact directly with the dsRNA substrate via their double stranded RNA binding domains. If an editing site occurs within a coding sequence, it can result in a codon change. This can lead to translation of a protein isoform due to a change in its primary protein structure. Therefore, editing can also alter protein function. A to I editing occurs in a non coding RNA sequences such as introns, untranslated regions (UTRs), LINEs, SINEs ( especially Alu repeats) The function of A to I editing in these regions is thought to involve creation of splice sites and retention of RNAs in the nucleus amongst others.

Location

[edit]

Editing occurs in 5 different closely located sites within exon 5, which corresponds to the second intracellular loop of the final protein. The sites are known as A, B, C′ (previously called E), C and D, and are predicted to occur within amino acid positions 156, 158 and 160. Several codon changes can occur due to A-to-I editing at these sites. Thirty-two different mRNA variants can occur leading to 24 different protein isoforms.

  1. An Isoleucine to Valine (I/V) at amino acid position 157,161.
  2. An Isoleucine to a Methionine(I/M) at amino acid position 157
  3. An Aspartate to a Serine (N/S)at 159
  4. An Aspartate to Asparagine(N/D) at 159
  5. An Asparagine to a Glycine(N/G) at 159.

These codon changes which can occur due to A to I editing at these sites can lead to a maximum of 32 different mRNA variants leading to 24 different protein isoforms. The number of protein isoforms is less than 32 since some amino acids are encoded by more than one codon.[44] Another editing site, site F has also been located in the exon complementary sequence (ECS) of intron 5.[45] The ECS required for formation of double stranded RNA structure is found within intron 5.[43]

Conservation

[edit]

RNA editing of this receptor occurs at 4 locations in the rat.[43] Editing also occurs in the mouse.[46] The initial demonstration of RNA editing in rat.[43] The predominant isoform in rat brain is VNV which differs from the most common type found in humans.[43][47] The editing complementary sequence is known to be conserved across Mammalia.

Regulation

[edit]

The 5-HT2c receptor is the only serotonin receptor edited despite its close sequence similarities to other family members.[47] 5HT2CR is different due to possessing an imperfect inverted repeat at the end of exon 5 and the beginning of intron 5 allowing formation of an RNA duplex producing the dsRNA required by ADARs for editing. Disruption of this inverted repeat was demonstrated to cease all editing.[43] The different 5HT2CR mRNA isoforms are expressed differently throughout the brain, yet not all of the 24 have been detected perhaps due to tissue specific expression or low frequency editing of a particular type. Those isoforms that are not expressed at all or at a very low frequency are linked by being edited only at site C' and/or site B but not at site A. Some examples of differences in frequency of editing and site edited in different parts of the human brain of 5HT2CR include low frequency of editing in cerebellum and nearly all editing is at site D while in the hippocampus editing frequency is higher with site A being the main editing site. Site C' is only found edited in the thalamus. The most common isoform in human brain is the VSV isoform.[44][47][48]

Mice knock out and other studies have been used to determine which ADAR enzyme are involved in editing. Editing at A and B sites has been demonstrated to be due to ADAR1 editing.[49][50][51] Also since ADAR1 expression is increased in response to the presence of interferon α, it was also observed that editing at A and B sites was also increased because of this.[49] C' and D sites require ADAR2 and editing is decreased by the presence of ADAR1 with editing of C' site only observed in ADAR1 double knock out mice.[52] The C site has been shown to be mainly edited by ADAR2 but in presence of upregulated expression of ADAR1, there was an increase in editing of this site and the enzymes presence can also result in limited editing in ADAR 2 knock out mice.[49][52] This demonstrates that there must be some form interaction between the two A to I editing enzymes. Also such interactions and tissue specific expression of ADARs interaction may explain the variety in editing patterns in different regions of the brain.

Consequences

[edit]

Second, the editing pattern controls the amount of the 5-HT2CR mRNA that leads to the expression of full-length protein through the modulation of alternative splice site selection 76,77. Among three alternative splice donor sites (GU1 to GU3; Fig. 4C), GU2 is the only site that forms the mature mRNA to produce the functional, full-length 5-HT2CR protein. Unedited pre-mRNAs tend to be spliced at the GU1 site, resulting in the truncated, non-functional protein if translated 76,77. However, most pre-mRNAs edited at more than one position are spliced at GU2 77. Thus, when editing is inefficient, increased splicing at GU1 may act as a control mechanism to decrease biosynthesis of the 5-HT2CR-INI and thereby limit serotonin response. Third, RNA editing controls the ultimate physiological output of constitutively active receptors by affecting the cell surface expression of the 5-HT2CR. The 5-HT2CR-VGV, which displays the lowest level of constitutive activity, is fully expressed at the cell surface under basal conditions and is rapidly internalized in the presence of agonist 78; additionally, in vitro, LSD shows negligible activity with this isoform.[53] In contrast, the 5-HT2CR-INI is constitutively internalized and accumulates in endosomes 78.

Structure

As mentioned editing results in several codon changes. The editing sites are found in the second intracellular domain of the protein which is also the receptors G protein coupling domain. Therefore, editing of these sites can affect the affinity of the receptor for G protein binding.[43]

Function

Editing results in reduced affinity for specific G proteins which in turn affects internal signalling via second messengers (Phospholipase C signalling system). The fully edited isoform, VGV, considerably reduces 5-HT potency, G-protein coupling and agonist binding, compared to the unedited protein isoform, INI. 72–76. Most evidence for the effect of editing on function comes from downstream measurements of receptor activity, radio ligand binding and functional studies. Inhibitory effects are linked to the extent of editing. Those isoforms with a higher level of editing require higher levels of serotonin to activate the phospholipase c pathway. Unedited INI form has a greater tendency to isomerise to an active form which can more easily interact with G proteins. This indicates that RNA editing here may be a mechanism for regulating neuronal excitability by stabilising receptor signalling.[43][47]

Editing is also thought to function in cell surface expression of the receptor subtype. The fully edited VGV, which has the lowest level of constitutive activity, is fully expressed at the cell surface while the non-edited INI is internalised and accumulates in endosome.[54]

Editing is also thought to influence splicing. Three different spliced isoforms of the receptor exist. Editing regulates the amount of 5HT2CR mRNA which leads to translation of the full length protein selection of alternative splice sites. t76,77. These splice sites are termed Gu1, Gu2, GU3. Only GU2 site splicing results in translation of the full length receptor while editing at GU1 is known to result in translation of a truncated protein. This is thought to be a regulatory mechanism to decrease the amount of unedited isoform INI to limit serotonin response when editing is inefficient. Most of the pre-mRNAs which are edited are spliced at the GU2 site.[45][48]

Dysregulation

Serotonin family of receptors are often linked to pathology of several human mental conditions such as Schizophrenia, anxiety, Bipolar disorder and major depression.[55] There have been several experimental investigations into the effects of alternative editing patterns of the 5HT2CR and these conditions with a wide variability in results especially those relating to schizophrenia.[56] Some studies have noted that there is an increase in RNA editing at site A in depressed suicide victims.[12][56] E site editing was observed to be increased in individuals with major depression.[57] In rat models this increase is also observed and can be reversed with fluoxetine with some suggestion that E site editing maybe linked to major depression.[58][59]

See also

[edit]

References

[edit]
[edit]

Further reading

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

5-HT2C receptor

View on Grokipedia
from Grokipedia
The 5-HT2C receptor, also known as 5-hydroxytryptamine receptor 2C and encoded by the HTR2C located on the at Xq23, is a seven-transmembrane (GPCR) that binds the serotonin (5-hydroxytryptamine) to mediate diverse physiological responses primarily in the . Its pre-mRNA undergoes extensive adenosine-to-inosine at five sites within the second intracellular loop, generating up to 32 distinct mRNA isoforms encoding 24 protein variants that variably attenuate coupling and receptor desensitization, thereby fine-tuning signaling efficiency. The 5-HT2C receptor is predominantly expressed in the , with high levels in regions such as the , , hippocampus, , , and , where it influences neuronal excitability and network activity. Upon ligand binding, it primarily couples to Gq/11 proteins, activating (PLC) to hydrolyze into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which mobilizes intracellular calcium and activates ; it also engages A2 (PLA2) and additional pathways like (ERK1/2). Physiologically, the receptor regulates key processes including and via actions in pro-opiomelanocortin (POMC) neurons of the arcuate nucleus, anxiety and responses in the , mood stabilization, motoneuron activity, and reward modulation through interactions with dopamine systems in the . Dysregulation of 5-HT2C receptor function, often linked to deficits or genetic polymorphisms, contributes to psychiatric and metabolic disorders such as depression, anxiety, , obsessive-compulsive disorder, drug addiction, and . Therapeutically, selective 5-HT2C agonists like (withdrawn in 2020 due to increased cancer risk) have been developed to promote by enhancing satiety without cardiovascular risks associated with non-selective serotonergics, while antagonists are investigated for alleviating negative symptoms in and enhancing efficacy; however, challenges include the receptor's homology with 5-HT2A, which can lead to off-target hallucinogenic effects. Recent studies as of 2025 explore its roles in disorders and psychedelic-assisted therapies for depression.

Molecular Structure

Gene Organization

The HTR2C gene, encoding the 5-HT2C receptor, is located on the long arm of the human X chromosome at cytogenetic band Xq23, spanning genomic coordinates X:114,584,086-114,910,061 (GRCh38 assembly). The gene encompasses approximately 326 kb of DNA and consists of seven exons separated by six introns, with the mature mRNA derived from alternative splicing of these elements. The coding region for the functional receptor protein is primarily distributed across exons 4 through 7, indicating introns interrupt the open reading frame. The promoter region upstream of the first exon lacks a canonical TATA box, a feature common to many G-protein-coupled receptor genes that rely on alternative basal transcription mechanisms. This TATA-less architecture contributes to the complex regulation of HTR2C expression in neural tissues. The gene undergoes post-transcriptional A-to-I RNA editing primarily within exon 5, generating protein isoform diversity without altering the overall genomic organization. The genomic structure of HTR2C, including its exon-intron arrangement and overall size, exhibits strong evolutionary conservation across mammalian species, with orthologs identified in over 200 vertebrates, reflecting its essential role in serotonin signaling. This conservation underscores the 's fundamental importance in function from to .

Protein Topology

The 5-HT2C receptor is a class A G-protein-coupled receptor (GPCR) characterized by a canonical seven-transmembrane topology, consisting of seven α-helical transmembrane domains (TM1–TM7) that span the plasma membrane, three extracellular loops (ECL1–ECL3) connecting the extracellular sides of the helices, three intracellular loops (ICL1–ICL3) on the cytoplasmic side, an extracellular N-terminal domain, and an intracellular C-terminal tail. High-resolution crystal structures of the 5-HT2C receptor, solved in 2018, confirm the canonical class A GPCR topology and reveal details of the orthosteric binding pocket. This architecture facilitates ligand binding in the orthosteric pocket formed primarily by residues from TM3, TM5, TM6, and TM7, as well as ECL2, while the intracellular loops and C-terminus mediate interactions with G-proteins and other effectors. The mature human 5-HT2C receptor protein comprises 458 , with an unglycosylated molecular weight of approximately 52 . Key structural features include an residue at position 120 (Asp3.32 in Ballesteros-Weinstein numbering) in TM3, which forms a with the positively charged group of serotonin and other ligands, stabilizing receptor-ligand interactions. Additionally, the conserved DRY motif (Asp-Arg-Tyr) at the junction of TM3 and ICL2 plays a critical role in G-protein activation by undergoing conformational changes upon binding to facilitate coupling with Gq/11 proteins. Post-translational modifications contribute to the receptor's structural maturation and membrane localization. N-linked glycosylation occurs at residues in ECL2 (notably Asn4.60), resulting in a mature of ~60 kDa that influences trafficking and stability. The 5-HT2C receptor exhibits higher to the 5-HT2A receptor (~50% identity overall, with greater conservation in transmembrane domains) than to the 5-HT2B receptor (~46% identity), reflecting shared evolutionary origins within the 5-HT2 subfamily while allowing subtype-specific selectivity. RNA-edited isoforms can alter the in ICL2, potentially affecting G-protein coupling efficiency without disrupting the core topology.

Genetics and RNA Editing

Genetic Variants

The HTR2C , located on the at Xq23, exhibits , resulting in hemizygosity in males and potential dosage compensation via in females, which may contribute to sex-specific effects on receptor expression and function. This chromosomal location can lead to differences in variant between sexes, as observed in association studies where male carriers show more pronounced phenotypic impacts compared to females. Among common polymorphisms, the -759T/C (rs3813929) variant in the promoter region influences transcriptional activity, with the T allele associated with reduced HTR2C mRNA expression compared to the C allele, acting as a cis-eQTL. This polymorphism has been linked to antipsychotic drug response in patients, particularly improved efficacy of in carriers of the C among males, though evidence for risk itself remains mixed. Another key variant is the Cys23Ser (rs6318) substitution in the , which alters receptor trafficking by causing endoplasmic reticulum retention and reduced cell surface expression, thereby diminishing signaling efficiency such as calcium mobilization. Population frequencies of the -759T/C variant vary by , with the minor T reaching approximately 24% in European cohorts, higher than in some Asian groups where it is around 12%. These differences underscore the need for ancestry-specific genetic analyses in clinical contexts. Rare mutations in HTR2C, including frameshift and missense variants, have been reported in neurodevelopmental disorders such as attention-deficit/hyperactivity disorder (ADHD) and , potentially disrupting receptor function and contributing to symptom severity. For instance, certain missense changes alter binding or signaling, with minor frequencies below 1% in affected individuals. Genetic variants in HTR2C may interact with RNA editing to further modulate receptor isoform diversity and functional outcomes, though this requires additional study.

RNA Editing Sites and Isoforms

The HTR2C gene, located on the at Xq23, undergoes A-to-I primarily at five sites (A through E) within 5, which encodes a 70-nucleotide region of the second intracellular loop (ICL2); this editing is catalyzed by 1 and 2 enzymes. These sites are clustered in a predicted double-stranded stem-loop that facilitates substrate recognition by the ADAR enzymes. Editing at these sites generates multiple mRNA isoforms through combinatorial deamination of adenosines to inosines, which are recognized as guanosines during translation and reverse transcription. Theoretically, the five sites allow for up to 32 mRNA variants, but due to interdependent editing efficiencies and structural constraints, approximately 14 isoforms are commonly observed in human brain tissue, with fewer in peripheral tissues. Notable examples include the fully unedited isoform INI (isoleucine-asparagine-isoleucine at positions 156, 158, and 160) and fully edited variants such as VSV (valine-serine-valine) or VGV (valine-glycine-valine), reflecting changes primarily at sites A, B, C, D, and E. Sites A, B, and C directly alter the amino acid sequence: site A changes Ile156 to Val156 (codon ATA to GTA), site B changes Asn158 to Asp158 (codon AAC to GAC), and site C changes Ile160 to Val160 (codon ATA to GTA), while sites D and E (the latter also termed C') are positioned within or adjacent to codon 158 and enable further variations at that residue, such as Ser158 (AGC from editing D) or Gly158 (GGC from editing both B and D). These amino acid substitutions in ICL2 reduce the receptor's constitutive activity by altering G-protein coupling efficiency. Editing patterns exhibit tissue specificity, with higher overall editing efficiency in the compared to peripheral tissues; for instance, human brain regions like the show predominant VSV isoforms (up to 50% edited), whereas peripheral samples display more unedited or partially edited forms. This differential editing contributes to region-specific receptor function, with tissues averaging 40-60% editing across sites versus less than 20% in non-neuronal tissues. Site-directed mutagenesis studies mimicking these editing-induced changes have confirmed site-specific impacts on receptor desensitization; for example, mutating residues at positions 156, 158, and 160 to edited forms (e.g., VSV) results in isoforms with prolonged desensitization upon stimulation, reduced potency, and altered internalization rates compared to the INI isoform.85266-6/fulltext) These experiments demonstrate that editing at individual sites, particularly B and C, distinctly modulates β-arrestin recruitment and receptor trafficking, thereby fine-tuning signaling duration.

Functional Consequences of Editing

RNA editing of the 5-HT2C receptor mRNA is primarily catalyzed by adenosine deaminases acting on (ADAR) enzymes, specifically ADAR1 and ADAR2, which convert to in double-stranded (dsRNA) structures. ADAR2 serves as the predominant enzyme for editing at sites A through D within the receptor's second intracellular loop (ICL2), while both enzymes contribute to site E editing; these enzymes localize to the nucleus, where the dsRNA substrate forms via base-pairing between 5 and adjacent sequences of the HTR2C pre-mRNA. The editing process is dynamically regulated, with ADAR expression upregulated by environmental stressors or antidepressant treatments such as , leading to altered editing patterns in brain regions like the . Additionally, feedback loops exist wherein 5-HT2C receptor activation via signaling elevates hexakisphosphate (IP6) levels, which in turn enhances ADAR2 activity and promotes further editing. Isoform-specific functional outcomes arise from these edits at five sites (A-E) in ICL2, generating up to 32 possible receptor variants. Unedited isoforms, such as INI, exhibit heightened Gq protein , elevated constitutive activity, and increased agonist-independent desensitization through GRK/β-arrestin pathways. In contrast, fully edited isoforms like VGV display reduced Gq efficiency, lower constitutive activity, diminished agonist potency, and attenuated desensitization, thereby fine-tuning serotonin signaling and receptor responsiveness. Pathological dysregulation of editing has been observed, with hyper-editing (increased editing at key sites) associated with depression and linked to enhanced receptor isoform diversity that dampens signaling, while hyper-editing correlates with heightened through low-activity edited forms. Furthermore, editing influences splice site selection in the HTR2C gene, where A-to-I changes near exon-intron boundaries alter splicing efficiency and contribute to isoform production. Editing efficiency varies across sites and tissues, with site C showing 50-90% editing in the human brain, higher than in rodents (e.g., ~60% in humans versus ~35% in rats), reflecting adaptive modulation of receptor function.87278-2/pdf)

Distribution and Expression

Central Nervous System

The 5-HT2C receptor displays the highest density of expression within the central nervous system in the choroid plexus, where it is abundantly localized to epithelial cells and contributes to the regulation of the blood-cerebrospinal fluid (CSF) barrier. Autoradiographic and mRNA studies have confirmed this enrichment, with receptor binding sites and transcripts far exceeding those in other brain regions, underscoring its prominent role in CSF production and composition. In contrast, moderate levels of expression are observed in several key limbic and cortical areas, including the prefrontal cortex, hippocampus, basal ganglia (particularly the caudate and nigrostriatal pathway), and amygdala, as identified through radioligand binding and in situ hybridization techniques in both rodent and primate models. Expression is notably lower in the and most nuclei, with minimal detection in granular layers of the and sparse distribution outside specific structures like the . At the cellular level, 5-HT2C receptors are primarily localized postsynaptically on , such as parvalbumin-positive cells in the , and on pyramidal neurons across cortical and limbic regions, enabling modulation of inhibitory and excitatory transmission. Additionally, lower levels of expression occur on , where receptor activation can influence signaling pathways like ERK1/2 in response to serotonin. Developmentally, 5-HT2C receptor expression undergoes upregulation in the postnatal period in , with mRNA and protein levels increasing progressively in regions like the and cortex, reaching peak abundance in adulthood to support maturing neural circuits. of the receptor transcript varies across brain regions, contributing to isoform diversity that may fine-tune regional functions.

Peripheral Tissues

The 5-HT2C receptor exhibits low overall expression in peripheral tissues compared to the , with detectable mRNA and protein levels in select organs based on transcriptomic and immunohistochemical analyses. In the human , expression is observed in the , including the , where 5-HT2C receptors contribute to serotonergic modulation of intestinal motility through excitatory signaling on neurons and interstitial cells. The 5-HT2C receptor shows low expression in the cardiovascular system. The receptor is also expressed in , where it participates in local serotonin-mediated regulation of function and . Moderate expression occurs in the , liver, and , supporting roles in endocrine and metabolic processes, while levels remain low in . Notable species differences exist in peripheral 5-HT2C expression, with displaying higher levels across multiple tissues relative to humans, which may influence translational studies on metabolic and gastrointestinal functions. Functionally, peripheral 5-HT2C receptors modulate insulin secretion in pancreatic β-cells, potentially linking to glycemic control. This peripheral distribution shows limited overlap with central circuits, primarily serving local tissue-specific roles.

Physiological Functions

Signal Transduction Pathways

The 5-HT2C receptor primarily couples to /11 proteins upon activation by serotonin or agonists, leading to the stimulation of (PLC). This activation results in the hydrolysis of (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 subsequently binds to receptors on the , triggering the release of intracellular calcium (Ca²⁺), while DAG activates (PKC), which phosphorylates downstream targets to modulate cellular responses. In addition to the canonical Gq/11 pathway, the 5-HT2C receptor engages secondary signaling cascades depending on cellular context and ligand. It can couple to Gi/o proteins, inhibiting and thereby reducing cyclic AMP (cAMP) levels. The receptor also interacts with G12/13 proteins, which activate Rho guanine exchange factors (RhoGEFs) to stimulate RhoA, influencing cytoskeletal dynamics. Furthermore, β-arrestin recruitment following receptor activation scaffolds and activates the (MAPK)/extracellular signal-regulated kinase (ERK) pathway, independent of signaling. The 5-HT2C receptor exhibits constitutive activity, particularly in its non-edited isoform (INI), where it spontaneously activates /11-mediated PLC signaling in the absence of . at multiple sites in the second intracellular loop reduces this basal activity by altering receptor conformation and impairing coupling efficiency, with fully edited isoforms (VGV) showing minimal constitutive signaling. Recent studies have identified biased agonism at the 5-HT2C receptor, where certain preferentially activate specific pathways. For instance, psychedelics like demonstrate stronger Gq/11 coupling compared to β-arrestin recruitment, potentially contributing to distinct physiological effects while minimizing off-target signaling. Receptor desensitization occurs through by kinases (GRKs), particularly GRK2, which creates binding sites for β-arrestins. β-Arrestin binding uncouples the receptor from G proteins, promotes internalization via clathrin-mediated , and can lead to either resensitization or downregulation depending on the and editing state.

Roles in Behavior and Homeostasis

The 5-HT2C receptor plays a significant role in modulating anxiety and mood through its expression in limbic and cortical regions. Antagonism of 5-HT2C receptors reduces anxiety-like behaviors in models, such as decreased time spent in open arms of the elevated plus-maze and reduced defensive burying. Similarly, 5-HT2C antagonists exhibit antidepressant-like effects in chronic unpredictable stress paradigms, enhancing resilience to depressive symptoms without altering baseline locomotor activity. These effects are mediated primarily through the /PLC signaling pathway, which influences neuronal excitability in anxiety-regulating circuits. In cognition and reward processing, 5-HT2C receptors contribute to executive functions via prefrontal cortical circuits. Activation of 5-HT2C receptors in the medial prefrontal cortex impairs cognitive flexibility, as evidenced by increased perseveration in reversal learning tasks in rats, while antagonism enhances performance in touchscreen-based assays. Regarding reward, 5-HT2C agonists like Ro60-0175 and lorcaserin dose-dependently reduce cocaine self-administration and cue-induced reinstatement in rodents, attenuating motivational drive for psychostimulants under fixed-ratio and progressive-ratio schedules. The 5-HT2C receptor influences sleep-wake regulation, particularly through its expression in hypothalamic and nuclei. In mice lacking 5-HT2C receptors, there is increased and reduced non-REM sleep, with altered REM sleep homeostasis during recovery from , indicating a role in stabilizing REM transitions. Pharmacological blockade of 5-HT2C receptors decreases REM sleep duration and non-REM to REM transitions, underscoring its contribution to REM promotion in hypothalamic circuits. In homeostatic processes, 5-HT2C receptors participate in and . Activation of central 5-HT2C receptors by agonists like m-chlorophenylpiperazine induces in rats, reflecting enhanced thermogenic responses in hypothalamic thermoregulatory centers. In the , 5-HT2C receptor expression on nociceptive neurons modulates transmission; agonists produce antiallodynic effects in neuropathic models via , reducing mechanical hypersensitivity. Conversely, some evidence suggests a pronociceptive role under certain conditions, highlighting context-dependent spinal modulation. The 5-HT2C receptor also regulates seizure susceptibility by promoting inhibitory activity and tonically suppressing neuronal hyperexcitability. Genetic of the receptor in mice leads to spontaneous s and increased seizure susceptibility, while agonists, such as bexicaserin, reduce frequency in models of developmental epileptic encephalopathies. Circuit-specific actions of the 5-HT2C receptor include inhibition of dopamine release in the . Striatal 5-HT2C receptors tonically suppress nigrostriatal transmission by enhancing inhibition on neurons in the , as demonstrated by increased efflux following selective antagonism. This inhibitory control contributes to balanced motor output and prevents excessive activity in circuits. Additionally, 5-HT2C receptors modulate spinal motor function, regulating both volitional and involuntary behaviors; loss-of-function variants alter motor patterns in male and female . As of 2025, agonism has been shown to enhance and strength in aged mice, suggesting a role in counteracting age-related motor decline such as .

Endocrinology

Appetite and Metabolic Regulation

The 5-HT2C receptor plays a pivotal role in appetite suppression through its expression in the arcuate nucleus of the , where activation inhibits orexigenic (NPY)/agouti-related peptide (AgRP) neurons and excites anorexigenic pro-opiomelanocortin (POMC)/- and amphetamine-regulated transcript (CART) neurons. This reciprocal regulation enhances signaling, promoting and reducing food-seeking via downstream projections to second-order neurons in the paraventricular nucleus. Selective 5-HT2C receptor agonists, such as lorcaserin, exert anorectic effects in animal models by reducing the size and duration of meals, leading to decreased overall caloric intake without significantly altering the frequency of eating episodes. In rodents, lorcaserin administration dose-dependently suppresses operant responding for food and ad libitum chow consumption, mimicking the receptor's endogenous role in meal termination. These effects are mediated centrally, as they persist in models with intact hypothalamic circuitry but are abolished in 5-HT2C receptor knockout animals. In humans, the therapeutic potential of 5-HT2C receptor agonism is exemplified by , which received FDA approval in 2012 for chronic in but was withdrawn in 2020 following post-marketing studies indicating an increased risk of cancer. Dysregulation of 5-HT2C receptor function, including altered and splicing, has been linked to hyperphagia in Prader-Willi syndrome, a characterized by insatiable appetite and . Knockout studies in mice confirm this, demonstrating that 5-HT2C receptor deletion results in hyperphagia, late-onset , and heightened susceptibility to diet-induced weight gain. Beyond appetite control, 5-HT2C receptor activation influences metabolic processes by enhancing in through central sympathetic outflow and improving insulin sensitivity in models of diet-induced . treatment reduces and enhances glucose tolerance independently of in some contexts, underscoring the receptor's broader role in . Peripheral expression in gut tissues may contribute modestly to these effects by modulating nutrient sensing.

Hormonal Interactions

The 5-HT2C receptor contributes to regulation through serotonergic pathways in the , particularly in the paraventricular nucleus, where it mediates serotonin-induced stimulation of release. Activation of 5-HT2C receptors inhibits tuberoinfundibular neurons, thereby reducing dopamine-mediated suppression of secretion from the . This interaction highlights the receptor's role in modulating under conditions like stress or hyperestrogenic states, where 5-HT2A/2C significantly elevates circulating levels. Antagonism of 5-HT2C receptors, as seen with certain pharmacological agents, attenuates these responses, though complex interactions with systems can influence net effects in clinical contexts. In function, 5-HT2C receptors participate in the modulation of thyrotropin-stimulating (TSH) secretion, with serotonergic signaling generally exerting inhibitory effects at the hypothalamic level. Administration of 5-HT2 antagonists like has been associated with increased TSH release in euthyroid subjects, suggesting tonic 5-HT2C-mediated suppression of TSH under normal conditions. This mechanism may link 5-HT2C dysregulation to symptoms of , such as anxiety and agitation, which overlap with serotonergic hyperactivity and altered thyroid feedback. The 5-HT2C receptor is expressed in gonadal tissues, influencing steroidogenesis and exhibiting sex differences in density and function. In species like , 5-HT2C mRNA is present in ovarian cells. These patterns underscore the receptor's role in reproductive physiology beyond central neural circuits. 5-HT2C receptors interact with the hypothalamic-pituitary-adrenal (HPA) axis to alter responses, primarily through activation in the paraventricular nucleus that stimulates (CRH) release and subsequent elevation. Genetic variations in the HTR2C , encoding the 5-HT2C receptor, predict heightened reactivity to stress, indicating its modulatory influence on HPA dynamics. This interaction is particularly relevant in stress-related endocrine disruptions, where 5-HT2C stimulation amplifies output. Pharmacological blockade of 5-HT2C receptors by antipsychotics, such as , elevates levels by disrupting inhibitory interactions between 5-HT2C and receptors (GHSR1a), thereby enhancing ghrelin signaling that promotes secretion. This effect contrasts with the receptor's typical suppressive role in hormonal and contributes to metabolic side effects observed in long-term treatment.

Pharmacology

Agonists

The endogenous for the 5-HT2C receptor is serotonin (5-HT), which binds with high affinity (pKi ≈ 8.0) and activates Gq-mediated signaling pathways. Synthetic full such as m-chlorophenylpiperazine (mCPP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) potently activate the 5-HT2C receptor but exhibit limited selectivity, also engaging 5-HT2A and 5-HT2B subtypes with comparable affinities. Partial agonists include lorcaserin, a selective compound with an EC50 of approximately 9 nM at 5-HT2C receptors, demonstrating full efficacy at this subtype while showing partial activity at 5-HT2A. Aripiprazole functions as a at 5-HT2C receptors as part of its broader multi-receptor profile, contributing to its effects with minimal weight gain liability. Biased agonists, particularly serotonergic psychedelics like and DOI, preferentially activate Gq/11 signaling over β-arrestin recruitment at 5-HT2C receptors, as revealed in 2025 signaling profiling studies. Structure-activity relationship studies of derivatives indicate that substitutions at the 4- or 5-position of the ring enhance 5-HT2C potency and selectivity, with N-benzyl modifications further optimizing efficacy. Clinical trials have evaluated 5-HT2C agonists such as (FDA-approved in 2012 but withdrawn in 2020 due to potential cancer risk) for , demonstrating significant in phase III studies, and vabicaserin (development discontinued circa 2012) for , showing antipsychotic efficacy without substantial weight gain in phase II trials.

Antagonists and Inverse Agonists

Antagonists of the 5-HT2C receptor block the binding of serotonin and inhibit receptor activation, while inverse agonists suppress both ligand-induced and constitutive receptor activity. These compounds are distinguished by their selectivity profiles, with non-selective agents often interacting with other serotonin receptor subtypes, particularly . Selective antagonists and inverse agonists have been instrumental in dissecting 5-HT2C-mediated functions in preclinical models. Non-selective antagonists such as and exhibit affinity for both 5-HT2C and 5-HT2A receptors. displays a Ki of approximately 200 nM at 5-HT2C receptors, effectively blocking serotonin-stimulated cyclic GMP formation in cells. , with a higher potency (Ki ≈ 1.3 nM), similarly antagonizes 5-HT2C signaling but also down-regulates both receptor subtypes upon chronic exposure in human neuroblastoma cells. These agents have been used in early pharmacological studies to probe 5-HT2 family involvement in behaviors like anxiety and locomotion. Selective 5-HT2C antagonists, including and RS-102221, offer greater specificity, with showing a pKi of approximately 9 and over 100-fold selectivity versus 5-HT2A. These compounds penetrate the and have demonstrated effects in rodent models without significant off-target activity at other serotonin receptors. Peripherally restricted antagonists like SB-206553, which exhibit limited penetration, are particularly useful for targeting peripheral 5-HT2C functions. Inverse agonists at the 5-HT2C receptor, such as SB-228357, reduce constitutive receptor activity independent of presence, as evidenced by decreased basal accumulation in cells expressing the receptor. SB-228357 displays high selectivity and potency, making it a tool for studying unliganded receptor signaling. , a , acts as a neutral at edited 5-HT2C receptors (VSV isoform), though it exhibits properties in certain contexts, contributing to its effects by enhancing frontal cortex release. In clinical contexts, 5-HT2C antagonism by atypical antipsychotics like and helps mitigate extrapyramidal side effects associated with D2 blockade. These drugs exhibit activity at constitutively active 5-HT2C receptors, which correlates with their reduced motor profile compared to typical antipsychotics. Peripherally selective 5-HT2C antagonists, such as derivatives of SB-206553, have been explored for gastrointestinal disorders by avoiding central effects while modulating enteric serotonin signaling to improve gut transit.

Allosteric Modulators

Allosteric modulators of the 5-HT2C receptor bind to sites distinct from the orthosteric serotonin-binding pocket, thereby influencing receptor conformation and modulating the efficacy or potency of orthosteric agonists without directly activating the receptor. Positive allosteric modulators (PAMs) enhance agonist-induced signaling, while negative allosteric modulators (NAMs) diminish it, offering a strategy to fine-tune receptor activity with potentially improved subtype selectivity over 5-HT2A and 5-HT2B receptors. This approach is particularly appealing for avoiding off-target effects associated with orthosteric ligands. A seminal example of a 5-HT2C PAM is PNU-69176E, which selectively potentiates serotonin-induced calcium mobilization and inositol phosphate accumulation by increasing agonist potency up to 10-fold without intrinsic agonist activity. Structurally featuring a long alkyl chain and an α-D-galactopyranoside polar moiety, PNU-69176E likely anchors in the membrane and interacts with an allosteric site involving transmembrane domains to stabilize the active receptor conformation. More recent PAMs, such as CYD-1-79 and VA012, demonstrate similar enhancement of serotonin efficacy (e.g., increasing Emax by approximately 20-127% in functional assays) and exhibit high selectivity for 5-HT2C over 5-HT2A and 5-HT2B. As of 2025, investigations into PAMs like CYD-1-79 have shown attenuation of cocaine cue reactivity in preclinical models by promoting biased Gi/o-coupled signaling over Gq. These compounds bind to extracellular vestibule regions or transmembrane helices, promoting biased signaling profiles that favor Gq-mediated pathways. Negative allosteric modulators of the 5-HT2C receptor are less extensively characterized but include compounds like Compound 1, which reduces serotonin-evoked calcium release in cellular assays by stabilizing inactive conformations and decreasing efficacy. Certain dual-acting ligands, such as Compound 5, function as PAMs at 5-HT2C while serving as NAMs at 5-HT2B, potentially mitigating valvulopathy risks associated with 5-HT2B activation. These NAMs typically interact with allosteric sites in the transmembrane bundle, reducing orthosteric ligand binding affinity or efficiency. Therapeutically, 5-HT2C PAMs hold promise for enhancing endogenous serotonin signaling with greater specificity, supporting applications in (e.g., VA012 reduces food intake in models) and neuropsychiatric disorders like depression through improved mood regulation. In , recent investigations highlight PAMs such as CYD-1-79, which attenuate cue reactivity in preclinical models by promoting biased Gi/o-coupled signaling over Gq, suggesting potential for interventions. Overall, allosteric modulation enables subtype-selective tuning, though clinical translation remains in early stages pending further optimization of and safety profiles.

Protein Interactions

Intracellular Signaling Partners

The 5-HT2C receptor primarily couples to heterotrimeric Gq/11 proteins, consisting of Gαq/11 subunits along with Gβ and Gγ subunits, to initiate intracellular signaling upon binding. This coupling occurs through the receptor's third intracellular loop and C-terminal tail, facilitating GDP-GTP exchange on the Gα subunit and subsequent dissociation of the heterotrimer. The interaction with Gq/11 is a core feature of 5-HT2C receptor activation, enabling downstream effector engagement in various neuronal and non-neuronal tissues. Among effectors, the 5-HT2C receptor activates phospholipase C-β (PLC-β) isoforms, particularly PLC-β1 and PLC-β3, which hydrolyze (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). The generated IP3 then binds to IP3 receptors (IP3R) on the , triggering calcium release into the and amplifying signaling cascades. This PLC-β-mediated pathway represents the primary Gq/11-dependent mechanism for 5-HT2C receptor function. Beta-arrestins, specifically β-arrestin-1 and β-arrestin-2, interact with the phosphorylated of the 5-HT2C receptor to promote desensitization by uncoupling it from G proteins and facilitating clathrin-mediated . Beyond desensitization, β-arrestins serve as scaffolds for extracellular signal-regulated (ERK1/2) activation, enabling G protein-independent signaling that modulates and cellular responses. This dual role underscores β-arrestins' importance in regulating 5-HT2C receptor trafficking and biased agonism. Additional partners include postsynaptic density protein 95 (PSD-95), which binds to the C-terminal PDZ-binding motif of the 5-HT2C receptor to anchor it at synaptic sites, enhancing receptor stability and localization in postsynaptic densities. (CaM) physically interacts with a Ca2+-dependent motif in the proximal C-tail of the receptor, influencing agonist-dependent and β-arrestin recruitment independent of activation. RNA editing of the 5-HT2C receptor pre-mRNA generates multiple isoforms that alter β-arrestin recruitment efficiency, with fully edited variants (e.g., 5-HT2C-VGV) exhibiting reduced constitutive association with β-arrestin-2 compared to non-edited forms. This editing-induced variation modulates desensitization rates and receptor trafficking, contributing to isoform-specific signaling profiles in the .

Receptor Heterodimerization

The 5-HT2C receptor, a (GPCR), engages in heterodimerization with other receptors, forming complexes that modulate its signaling properties and physiological roles. These interactions occur primarily through transmembrane (TM) domains, with biophysical evidence from bioluminescence resonance energy transfer (BRET) and (FRET) assays demonstrating specific dimer interfaces at TM4 and TM5. Such oligomerization influences receptor conformation, affinity, and intracellular trafficking, often resulting in allosteric effects that alter functional outcomes. For instance, heterodimer formation can reduce binding affinity or promote receptor internalization, thereby fine-tuning serotonin-mediated responses in key brain regions like the cortex and . Heterodimerization of the 5-HT2C receptor with the has been observed in cortical regions, where the 5-HT2C protomer exerts a dominant influence, masking 5-HT2A signaling efficacy through complex formation. BRET, luminescence complementation assay (LCA), and proximity ligation assay (PLA) studies in transfected cells confirm this interaction, showing that 5-HT2C-containing heterodimers exhibit preserved Gq coupling via 5-HT2C and decreased 5-HT2A responsiveness to serotonin agonists. This cortical heterodimerization has implications for hallucinogen tolerance, as chronic exposure to psychedelics like , which primarily target 5-HT2A, may indirectly desensitize 5-HT2C activity via these complexes, contributing to diminished behavioral effects over time. In the , 5-HT2C receptors form heterodimers with D2 receptors, modulating locomotor activity through integrated dopaminergic-serotonergic signaling. These complexes lead to synergistic enhancement of 5-HT2C-mediated activation and attenuation of D2-mediated inhibition, providing fine-tuned control of striatal release. Functional studies indicate that D2-5-HT2C heterodimers in this region contribute to suppression of excessive locomotion, providing a molecular basis for 5-HT2C's role in motor regulation. The 's dense expression of these interacting receptors supports their relevance in such behavioral contexts.

Clinical Significance

Associations with Disorders

The 5-HT2C receptor has been implicated in the of several disorders through dysregulation of its expression and function. In , reduced of the 5-HT2C receptor mRNA has been observed in postmortem brain tissue, leading to of the receptor and altered serotonergic signaling that may contribute to dopaminergic imbalances in the . A of genetic studies on the Ser23Cys polymorphism in the HTR2C indicated an association with better response in , with an of approximately 2.0 for the Ser23 in males, highlighting its role in treatment outcomes. In obsessive-compulsive disorder (OCD), evidence suggests hyperfunction of the 5-HT2C receptor, as models exhibit increased compulsive behaviors such as excessive grooming, and pharmacological blockade of the receptor attenuates compulsive-like responses in animal paradigms relevant to OCD. Neurological disorders also show links to 5-HT2C receptor dysregulation. Promoter variants and loss-of-function mutations in the HTR2C gene have been associated with increased risk of , particularly (SUDEP), where enrichment of non-synonymous variants disrupts serotonergic modulation of seizure thresholds and respiratory control. In , altered 5-HT2C receptor activity influences dopamine modulation in the , with increased receptor binding in the pars reticulata contributing to motor symptoms and through interactions with . Metabolic disorders are strongly tied to 5-HT2C receptor polymorphisms that affect regulation. The promoter polymorphism HTR2C -759C/T (rs3813929) is associated with susceptibility, particularly in women, with the C linked to higher risk (OR 1.72) and greater by increasing receptor expression and signaling; the T reduces expression and protects against in studies. In Prader-Willi syndrome, imprinting defects at the 15q11-q13 locus lead to loss of non-coding RNAs that regulate 5-HT2C receptor and splicing, resulting in disrupted receptor-mediated control and hyperphagia characteristic of the disorder. Beyond these categories, the 5-HT2C receptor is associated with and trauma-related conditions. models demonstrate increased preference for and enhanced reinforcing effects, indicating that receptor absence heightens vulnerability to psychostimulant through unchecked responses in the . In (PTSD), elevated of the 5-HT2C receptor in the central nucleus of the (CeA) correlates with resilience deficits, as observed in rodent models where editing changes exacerbate fear responses and PTSD-like behaviors.

Therapeutic Targeting

The 5-HT2C receptor has been targeted therapeutically primarily through agonists for obesity and antagonists incorporated into antipsychotics, though challenges such as off-target effects have limited progress. Lorcaserin, a selective 5-HT2C agonist, was approved by the FDA in 2012 for chronic weight management in obese or overweight adults but was voluntarily withdrawn from the market in 2020 after a post-marketing study indicated an increased risk of cancer, with incidence rates of 7.8% in lorcaserin-treated patients versus 7.2% in placebo, outweighing its modest weight loss benefits of approximately 3-5% body weight reduction. Iloperidone, an atypical antipsychotic approved in 2009 for schizophrenia, exerts partial antagonism at 5-HT2C receptors alongside stronger blockade of 5-HT2A and D2 receptors, contributing to its efficacy in reducing positive symptoms with a lower risk of extrapyramidal side effects compared to typical antipsychotics. In the drug development pipeline, selective 5-HT2C agonists like vabicaserin showed promise in phase II trials for , demonstrating improvements in positive and negative symptoms without significant weight gain, but development was halted around 2014 due to failure to meet primary efficacy endpoints in later studies. For , 5-HT2C antagonists such as , which combines 5-HT2C antagonism with melatonin receptor agonism, have been utilized in treating with comorbid sleep disturbances, enhancing and reducing wakefulness after sleep onset in clinical evaluations. Key challenges in 5-HT2C-targeted therapies include cross-reactivity with the , where agonism can induce cardiac valvulopathy through mitogenic signaling in cells, as observed with earlier serotonergic agents like ; this risk necessitates rigorous selectivity screening in preclinical models. Additionally, the X-linked genomic location of the HTR2C gene leads to sex-specific expression differences, with males being hemizygous and potentially more sensitive to variants like the Cys23Ser polymorphism, influencing therapeutic responses in disorders such as and depression. Recent studies on serotonergic psychedelics highlight biased agonists that preferentially activate /11 signaling over β-arrestin pathways at 5-HT2C receptors, potentially contributing to rapid effects in without full hallucinogenic profiles; for instance, analyses of compounds like reveal such bias, supporting their exploration in mood disorders. Positive allosteric modulators (PAMs) of 5-HT2C receptors are emerging for substance use disorders (SUD), enhancing endogenous serotonin signaling to reduce reward-seeking behaviors in preclinical models of alcohol and psychostimulant dependence. As of 2025, further research includes 5-HT2C modulation for disorders via full agonism or PAMs, and of selective agonists for alcohol use disorder and Prader-Willi syndrome hyperphagia. Ongoing clinical efforts include phase II trials evaluating 5-HT2C modulation as augmentation therapy in , building on historical data from vabicaserin to improve negative symptoms when added to standard antipsychotics. Biomarkers such as RNA editing levels of HTR2C mRNA, which generate up to 14 isoforms altering receptor constitutive activity, are being investigated to predict therapeutic outcomes and personalize treatments in psychiatric conditions like and depression.

References

  1. https://www.ncbi.nlm.nih.gov/gene/3358
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC5873585/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3124806/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC3080299/
  5. https://pubmed.ncbi.nlm.nih.gov/15935077/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8334728/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC6761005/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC6142049/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC12602058/
  10. https://pubs.acs.org/doi/10.1021/acschemneuro.5c00647
  11. https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147246
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC3350401/
  13. https://www.sciencedirect.com/science/article/pii/S0169328X96001738
  14. https://academic.oup.com/nar/article/32/7/2113/1095958
  15. https://www.ensembl.org/Homo_sapiens/Gene/Compara_Ortholog?db=core;g=ENSG00000147246
  16. https://www.cell.com/cell/fulltext/S0092-8674(18)30001-1
  17. https://www.sciencedirect.com/topics/neuroscience/5-ht2c-receptor
  18. https://hmdb.ca/proteins/HMDBP02700
  19. https://pubmed.ncbi.nlm.nih.gov/8750891/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC5860131/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC5328611/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC6384235/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC6853916/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC2686719/
  25. https://bmcresnotes.biomedcentral.com/articles/10.1186/1756-0500-2-71
  26. https://www.researchgate.net/publication/40688000_A_genetic_variant_of_HTR2C_may_play_a_role_in_the_manifestation_of_Tourette_syndrome
  27. https://www.nature.com/articles/s41591-022-02106-5
  28. https://pubmed.ncbi.nlm.nih.gov/10092629/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC407821/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC3225646/
  31. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01390/full
  32. https://pubmed.ncbi.nlm.nih.gov/9153397/
  33. https://www.nature.com/articles/1395328
  34. https://pubmed.ncbi.nlm.nih.gov/11282248/
  35. https://pubmed.ncbi.nlm.nih.gov/14602721/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC6971223/
  37. https://academic.oup.com/oons/article/doi/10.1093/oons/kvac010/6640459
  38. https://rupress.org/jcb/article/169/5/745/51685/ADAR2-mediated-editing-of-RNA-substrates-in-the
  39. https://www.mdpi.com/2073-4425/11/8/872
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC3629306/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC2946438/
  42. https://pubmed.ncbi.nlm.nih.gov/18554725/
  43. https://pubmed.ncbi.nlm.nih.gov/23247076/
  44. https://link.springer.com/article/10.1007/PL00022053
  45. https://www.researchgate.net/publication/227875645_Regional_distribution_and_cellular_localization_of_5-HT2C_receptor_mRNA_in_monkey_brain_Comparison_with_3Hmesulergine_binding_sites_and_choline_acetyltransferase_mRNA
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC2913252/
  47. https://pubmed.ncbi.nlm.nih.gov/15652696/
  48. https://pubmed.ncbi.nlm.nih.gov/20450948/
  49. https://www.mdpi.com/1420-3049/27/5/1680
  50. https://www.proteinatlas.org/ENSG00000147246-HTR2C/tissue/small%2Bintestine
  51. https://academic.oup.com/mend/article/24/10/1978/2738015
  52. https://www.proteinatlas.org/ENSG00000147246-HTR2C/tissue
  53. https://onlinelibrary.wiley.com/doi/10.1155/2017/7138926
  54. https://pubmed.ncbi.nlm.nih.gov/23349838/
  55. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.694204/full
  56. https://www.heffter.org/wp-content/uploads/2020/04/chap5.pdf
  57. https://molecularbrain.biomedcentral.com/articles/10.1186/s13041-014-0049-y
  58. https://pubmed.ncbi.nlm.nih.gov/14722258/
  59. https://www.molbiolcell.org/doi/10.1091/mbc.e08-04-0422
  60. https://molpharm.aspetjournals.org/article/S0026-895X%2824%2905002-8/abstract
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC6767919/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC8092707/
  63. https://www.sciencedirect.com/science/article/pii/S0021925818526661
  64. https://pubmed.ncbi.nlm.nih.gov/18523738/
  65. https://www.nature.com/articles/s41398-022-01815-2
  66. https://pubmed.ncbi.nlm.nih.gov/32579979/
  67. https://www.sciencedirect.com/science/article/pii/S0166432820304794
  68. https://pubmed.ncbi.nlm.nih.gov/26007324/
  69. https://www.nature.com/articles/npp2012258
  70. https://pubmed.ncbi.nlm.nih.gov/17653111/
  71. https://pubmed.ncbi.nlm.nih.gov/26427596
  72. https://www.nature.com/articles/1395943
  73. https://www.sciencedirect.com/science/article/abs/pii/S0893133X02003536
  74. https://pubmed.ncbi.nlm.nih.gov/8867872/
  75. https://www.sciencedirect.com/science/article/abs/pii/S0304395903005013
  76. https://www.sciencedirect.com/science/article/pii/S0006899311001417
  77. https://www.nature.com/articles/374542a0
  78. https://practicalneurology.com/news/treatment-with-bexicaserin-associated-with-seizure-frequency-reduction-for-people-with-developmental-and-epileptic-encephalopathies/2473786/
  79. https://pubmed.ncbi.nlm.nih.gov/25073477/
  80. https://pubmed.ncbi.nlm.nih.gov/15668911/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC12515959/
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC12181463/
  83. https://www.sciencedirect.com/science/article/pii/S0896627306004570
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC4436859/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC4710672/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC5362069/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC8421305/
  88. https://pubmed.ncbi.nlm.nih.gov/27931246/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC10058696/
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC5611374/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC2075535/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC11475328/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC8836087/
  94. https://www.karger.com/Article/Pdf/126251
  95. https://www.nature.com/articles/1300412
  96. https://www.sciencedirect.com/science/article/pii/S0304394014007289
  97. https://link.springer.com/article/10.1007/BF02246407
  98. https://www.sciencedirect.com/science/article/abs/pii/0306453084900179
  99. https://pubmed.ncbi.nlm.nih.gov/11840307/
  100. https://pubmed.ncbi.nlm.nih.gov/22521866/
  101. https://www.jneurosci.org/content/27/26/6956
  102. https://www.sciencedirect.com/science/article/abs/pii/S0306453016301123
  103. https://www.sciencedirect.com/science/article/abs/pii/S016643282400041X
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC3722531/
  105. https://pubmed.ncbi.nlm.nih.gov/9225287/
  106. https://pubmed.ncbi.nlm.nih.gov/8082704/
  107. https://www.researchgate.net/publication/10818897_5HT2C_Receptor_Agonists_as_Potential_Drugs_for_the_Treatment_of_Obesity
  108. https://onlinelibrary.wiley.com/doi/full/10.1038/oby.2008.537
  109. https://pubmed.ncbi.nlm.nih.gov/23469329/
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC9970836/
  111. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market
  112. https://adisinsight.springer.com/drugs/800021225
  113. https://pubmed.ncbi.nlm.nih.gov/18600561/
  114. https://pubmed.ncbi.nlm.nih.gov/23027415/
  115. https://pubmed.ncbi.nlm.nih.gov/9225286/
  116. https://pubmed.ncbi.nlm.nih.gov/7798914/
  117. https://pubmed.ncbi.nlm.nih.gov/9282925/
  118. https://www.nature.com/articles/npp201072
  119. https://www.sciencedirect.com/topics/neuroscience/5-ht2c-antagonists
  120. https://pubmed.ncbi.nlm.nih.gov/10737744/
  121. https://pubmed.ncbi.nlm.nih.gov/20946699/
  122. https://pubmed.ncbi.nlm.nih.gov/10991983/
  123. https://www.mdpi.com/1424-8247/17/6/695
  124. https://www.nature.com/articles/s41386-018-0190-x
  125. https://pubmed.ncbi.nlm.nih.gov/12815163/
  126. https://www.sciencedirect.com/science/article/pii/S0223523418311164
  127. https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00994
  128. https://www.pnas.org/doi/10.1073/pnas.1321576111
  129. https://www.uniprot.org/uniprotkb/P28335/entry
  130. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00907/full
  131. https://www.embopress.org/doi/10.1093/emboj/21.10.2332
  132. https://pmc.ncbi.nlm.nih.gov/articles/PMC2575147/
  133. https://www.jbc.org/article/S0021-9258%2818%2952666-1/fulltext
  134. https://pmc.ncbi.nlm.nih.gov/articles/PMC3973609/
  135. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0203137
  136. https://www.sciencedirect.com/science/article/abs/pii/S0165032725004756
  137. https://www.nature.com/articles/npp2013148
  138. https://pmc.ncbi.nlm.nih.gov/articles/PMC5329890/
  139. https://pubmed.ncbi.nlm.nih.gov/11443520/
  140. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2019.00058/full
  141. https://pubmed.ncbi.nlm.nih.gov/12782219/
  142. https://pubmed.ncbi.nlm.nih.gov/9582253/
  143. https://pubmed.ncbi.nlm.nih.gov/15048662/
  144. https://molecularbrain.biomedcentral.com/articles/10.1186/s13041-016-0277-4
  145. https://www.jneurosci.org/content/22/22/10039
  146. https://www.nature.com/articles/s41398-021-01252-7
  147. https://pmc.ncbi.nlm.nih.gov/articles/PMC2846148/
  148. https://www.sciencedirect.com/topics/neuroscience/5-ht2c-receptor-agonists
  149. https://pmc.ncbi.nlm.nih.gov/articles/PMC11073569/
  150. https://pubmed.ncbi.nlm.nih.gov/10994642/
  151. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.16233
  152. https://reporter.nih.gov/project-details/11061454
  153. https://www.fpwr.org/fpwr-funded-projects/the-5-ht2cr-mining-a-new-experimental-approach-to-therapeutics-for-prader-willi-syndrome
  154. https://www.researchgate.net/publication/231742071_5-HT2C_Agonists_as_Therapeutics_for_the_Treatment_of_Schizophrenia
  155. https://www.nature.com/articles/s41398-022-01938-6
Add your contribution
Related Hubs
User Avatar
No comments yet.